Physician
Mountain View Pediatrics PA
Mountain View Pediatrics PA was paid $22.64M by Medicaid between Jan 2018 and Dec 2024, across 101 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 23% of everything it billed.
33Billing provider infoMOUNTAIN VIEW PEDIATRICS PA
MORGANTON, NC 28655
MORGANTON, NC 28655
33aNPI1134118292assigned 10/20/2005
33bProvider typePediatrics Physician
28Total paid$22.64M
24GClaims1,263,557
24DCodes billed101
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in North Carolina
Rank by total paid#5 of 433
Median peer was paid$942K
This provider vs. median24×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 84,344 | $2.52M | |
| 2019 | 84,611 | $2.76M | |
| 2020 | 66,664 | $2.07M | |
| 2021 | 155,605 | $3.41M | |
| 2022 | 277,287 | $4.35M | |
| 2023 | 288,110 | $3.94M | |
| 2024incomplete | 306,936 | $3.59M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 23% | 86,256 | 73,938 | $5.17M |
| 99199 | Unlisted special service, procedure or report | 16% | 680,585 | 310,287 | $3.62M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 11% | 29,024 | 25,478 | $2.60M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 6.5% | 17,907 | 15,648 | $1.48M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 6.3% | 16,541 | 14,816 | $1.43M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 6.1% | 15,306 | 13,634 | $1.38M |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 4.2% | 49,697 | 43,500 | $945K |
| 90472 | Immunization administration, each additional vaccine (list separately) | 4.0% | 29,434 | 25,755 | $900K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.6% | 8,442 | 7,106 | $818K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.9% | 10,309 | 9,172 | $647K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.2% | 17,394 | 15,539 | $501K |
| D0145 | Oral evaluation for a patient under three years of age | 2.0% | 13,346 | 11,958 | $453K |
89 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.7% | 8,021 | $385K |
| 99401 | 1.5% | 11,290 | $343K | |
| 99051 | 1.1% | 10,025 | $253K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.0% | 23,367 | $234K |
| D1206 | Topical application of fluoride varnish | <1% | 13,344 | $200K |
| 90474 | <1% | 8,448 | $163K | |
| 87070 | <1% | 15,563 | $157K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 3,231 | $127K |
| 96127 | <1% | 14,479 | $81K | |
| 90651 | <1% | 2,788 | $70K | |
| 99381 | <1% | 706 | $61K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,445 | $50K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,439 | $47K |
| 80061 | Lipid panel | <1% | 2,696 | $41K |
| 96161 | <1% | 10,237 | $36K | |
| 92551 | <1% | 30,421 | $34K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,341 | $31K |
| 0002A | <1% | 489 | $30K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,411 | $27K |
| 0001A | <1% | 541 | $26K | |
| 83655 | <1% | 1,874 | $24K | |
| 0071A | <1% | 395 | $23K | |
| 0072A | <1% | 339 | $22K | |
| 94010 | <1% | 905 | $22K | |
| 90734 | <1% | 1,099 | $20K | |
| 90686 | <1% | 16,251 | $20K | |
| 99173 | <1% | 30,441 | $18K | |
| 85018 | <1% | 7,611 | $17K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,669 | $15K |
| 87634 | <1% | 513 | $15K | |
| 87807 | <1% | 1,098 | $14K | |
| 96160 | <1% | 3,884 | $13K | |
| 90620 | <1% | 831 | $9K | |
| 69210 | <1% | 201 | $9K | |
| 90619 | <1% | 819 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 815 | $8K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 1,604 | $7K |
| 0003A | <1% | 97 | $6K | |
| 0053A | <1% | 91 | $6K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 62 | $4K |
| 99442 | <1% | 84 | $4K | |
| E0570 | Nebulizer, with compressor | <1% | 27 | $4K |
| A4627 | Spacer, bag or reservoir, with or without mask, for use with metered dose inhaler | <1% | 80 | $3K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 20 | $3K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 26 | $3K |
| 90715 | <1% | 349 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 184 | $2K |
| 96380 | <1% | 100 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 62 | $920.68 |
| 90473 | <1% | 42 | $858.90 | |
| 0124A | <1% | 15 | $845.00 | |
| 82947 | <1% | 174 | $808.67 | |
| 81001 | <1% | 227 | $807.27 | |
| 90633 | <1% | 4,433 | $787.54 | |
| 90661 | <1% | 1,381 | $489.75 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 213 | $449.32 |
| 94664 | <1% | 37 | $412.14 | |
| 99441 | <1% | 12 | $407.16 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 40 | $376.14 |
| 90677 | <1% | 1,798 | $260.81 | |
| A7006 | Administration set, with small volume filtered pneumatic nebulizer | <1% | 27 | $247.09 |
| 90670 | <1% | 12,096 | $220.26 | |
| 90672 | <1% | 148 | $118.20 | |
| 94760 | <1% | 1,294 | $110.61 | |
| 81025 | <1% | 17 | $109.20 | |
| 91300 | <1% | 687 | $25.57 | |
| 90710 | 0% | 978 | $0.00 | |
| 90700 | 0% | 163 | $0.00 | |
| 90685 | 0% | 194 | $0.00 | |
| 90707 | 0% | 194 | $0.00 | |
| 99072 | 0% | 971 | $0.00 | |
| 90687 | 0% | 19 | $0.00 | |
| 91312 | 0% | 15 | $0.00 | |
| 91311 | 0% | 27 | $0.00 | |
| 90680 | 0% | 8,357 | $0.00 | |
| 90698 | 0% | 8,211 | $0.00 | |
| 90744 | 0% | 2,867 | $0.00 | |
| 90688 | 0% | 146 | $0.00 | |
| 90697 | 0% | 2,357 | $0.00 | |
| 99000 | 0% | 4,293 | $0.00 | |
| 91305 | 0% | 130 | $0.00 | |
| 90696 | 0% | 312 | $0.00 | |
| 1005F | 0% | 244 | $0.00 | |
| 90723 | 0% | 93 | $0.00 | |
| 99174 | 0% | 131 | $0.00 | |
| 91307 | 0% | 790 | $0.00 | |
| 90647 | 0% | 146 | $0.00 | |
| 90381 | 0% | 30 | $0.00 | |
| 90716 | 0% | 194 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWHALLEY, JOHN (PRESIDENT)